Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.

Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett JB, Mukhopadhyay P, Wagner S, Davis C.

Oncol Res Treat. 2015;38(3):88-94. doi: 10.1159/000375392. Epub 2015 Feb 20.

PMID:
25792079
2.

Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.

Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D, Jones TH.

Andrology. 2014 Nov;2(6):819-34. doi: 10.1111/andr.274. Epub 2014 Oct 1.

PMID:
25269643
3.

Heterogeneity of response to biologic treatment: perspective for psoriasis.

Edson-Heredia E, Sterling KL, Alatorre CI, Cuyun Carter G, Paczkowski R, Zarotsky V, Maeda-Chubachi T.

J Invest Dermatol. 2014 Jan;134(1):18-23. doi: 10.1038/jid.2013.326. Epub 2013 Aug 6.

4.

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data.

Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L.

Int J Clin Pract. 2013 Jan;67(1):32-45. doi: 10.1111/ijcp.12044. Epub 2012 Oct 22. Review.

PMID:
23082930
5.

Chronic kidney disease in gout in a managed care setting.

Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E.

BMC Nephrol. 2011 Aug 3;12:36. doi: 10.1186/1471-2369-12-36.

6.

A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.

Alatorre CI, Carter GC, Chen C, Villarivera C, Zarotsky V, Cantrell RA, Goetz I, Paczkowski R, Buesching D.

Int J Clin Pract. 2011 Aug;65(8):831-47. doi: 10.1111/j.1742-1241.2011.02703.x. Epub 2011 Jul 1. Review.

PMID:
21718398
7.

Review of treatment response in rheumatoid arthritis: assessment of heterogeneity.

Goetz I, Carter GC, Lucero M, Zarotsky V, Alatorre CI, Cantrell RA, Paczkowski R, Sterling KL.

Curr Med Res Opin. 2011 Apr;27(4):697-711. doi: 10.1185/03007995.2010.549805. Epub 2011 Jan 27. Review.

PMID:
21271796
8.

A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity.

Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Carter GC, Goetz I, Paczkowski R, Sierra-Johnson J.

Diabetes Obes Metab. 2010 Oct;12(10):845-57. doi: 10.1111/j.1463-1326.2010.01248.x. Review.

PMID:
20920036
9.

Burden of illness among patients at high risk versus low risk for major cardiovascular events.

Harley C, Sander SD, Zarotsky V, Cao F, Shah H.

J Med Econ. 2010;13(3):438-46. doi: 10.3111/13696998.2010.496341.

PMID:
20662626
10.

Predictors of adherence among Alzheimer's disease patients receiving oral therapy.

Borah B, Sacco P, Zarotsky V.

Curr Med Res Opin. 2010 Aug;26(8):1957-65. doi: 10.1185/03007995.2010.493788.

PMID:
20569067
11.

Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.

Burke JP, Sander S, Shah H, Zarotsky V, Henk H.

Curr Med Res Opin. 2010 May;26(5):1023-30. doi: 10.1185/03007991003670563.

PMID:
20199138
12.

Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.

Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D.

Curr Med Res Opin. 2010 Apr;26(4):777-85. doi: 10.1185/03007990903579171.

PMID:
20095797
13.

The economics of upper gastrointestinal bleeding in a US managed-care setting: a retrospective, claims-based analysis.

Cryer BL, Wilcox CM, Henk HJ, Zlateva G, Chen L, Zarotsky V.

J Med Econ. 2010 Mar;13(1):70-7. doi: 10.3111/13696990903526676.

PMID:
20047365
14.

GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting.

Halpern R, Kothari S, Fuldeore M, Zarotsky V, Porter V, Dabbous O, Goldstein JL.

Dig Dis Sci. 2010 Feb;55(2):328-37. doi: 10.1007/s10620-009-0927-9. Epub 2009 Aug 21.

15.

Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.

Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM.

Curr Med Res Opin. 2009 Sep;25(9):2251-8. doi: 10.1185/03007990903155915.

PMID:
19622006
16.

Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.

Toth PP, Zarotsky V, Sullivan JM, Laitinen D.

Cardiovasc Diabetol. 2009 May 18;8:26. doi: 10.1186/1475-2840-8-26.

17.

Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.

Borah BJ, Huang X, Zarotsky V, Globe D.

Curr Med Res Opin. 2009 Jun;25(6):1365-77. doi: 10.1185/03007990902896386.

PMID:
19425902
18.

Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.

Toth PP, Zarotsky V, Sullivan JM, Laitinen D.

Curr Med Res Opin. 2009 Jun;25(6):1355-63. doi: 10.1185/03007990902910450.

PMID:
19425901
20.

Lipid therapy utilization rates in a managed-care mixed dyslipidemia population.

Toth PP, Zarotsky V, Sullivan JM, Laitinen D.

J Clin Lipidol. 2008 Oct;2(5):365-74. doi: 10.1016/j.jacl.2008.08.443. Epub 2008 Aug 22.

PMID:
21291762
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk